Premier Research Expands its Medical Device Operations to the United States
PHILADELPHIA, March 11 /PRNewswire/-Premier Research Group Limited, the international clinical services group, is pleased to announce that it has expanded their medical device operations to include full coverage in the United States. Their dedicated medical device group has been offering clinical trials services in Europe since 1997 and is considered an industry leader for managing medical device trials and support services.
"Our clients have requested expanded medical device services, and we are committed to responding to these needs," explained Premier Research Group COO Dr. Troy McCall. "Providing both US and EU medical devices services is a strategic focus for our company and this will strengthen our ability to respond to customer's needs as well as offer a broader range of services for the global market."
U.S. medical device operations will be overseen by Efraim Roe Kozorovitsky, Executive Director, Medical Devices, and a 4-year veteran of the company. Mr. Roe has relocated from Switzerland to the United States. "Since July 2008, we have been establishing the infrastructure for our capabilities in the U.S. and today we are pleased to announce that we have the expertise in place to deliver the same quality that we have been providing in Europe for the past ten years. I look forward to growing this group," he commented.
About Premier Research
Premier Research is a leading global solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for analgesia, neuroscience, oncology, and infectious disease and have a wealth of experience in medical device and pediatric research.
Premier Research has 30 offices and operates in more than 30 countries across North America and Europe employing more 1,200 clinical professionals dedicated first and foremost to fulfilling each client's requirements in a timely, accurate, and cost-effective manner. This includes a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at our well-established network of dedicated clinical sites.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
